What Orion Biotechnology does

Orion Biotechnology is a clinical-stage, privately held biotechnology company headquartered in Ottawa, Canada, with additional operations in Krakow (Poland) and Geneva (Switzerland). The company focuses on discovering and developing precision-engineered peptide and small protein therapeutics that target G Protein-Coupled Receptors (GPCRs), with a current pipeline weighted toward obesity and metabolic disorders (two GPR75 candidates, a GIPR program, an Amylin program) and an oncology extension via a CXCR6 first-in-class immunotherapy candidate. The company's central asset is its proprietary PROcisionX™ discovery platform, which combines cell-based phage display screening (bypassing receptor purification), proprietary multiplex chemical synthesis, structure-activity matrix evaluation across cell-based assays, and in silico plus lab-based refinement to produce optimized leads from target identification in under six months — a fraction of typical industry timelines, per the company. Demonstrated outputs include a first-in-class CXCR6 molecule discovered in four months and GIPR leads generated in under four months.

Orion's business model is built around monetization through out-licensing of drug candidates, R&D collaborations centered on the PROcisionX™ platform, and potential strategic co-development partnerships with pharmaceutical and biotechnology companies. The company is pre-revenue, with funding to date totaling approximately $20.3M across a 2018 Polish R&D grant, a 2021 $11.5M equity round led by Keiretsu Forum, and a 2024 ~$6.8M round. Its Scientific Advisory Board is chaired by Nobel laureate Sir Gregory Winter, and its management and board include senior pharma veterans from Novo Nordisk, Novartis, Lexicon, Eli Lilly, Pfizer, and Johnson & Johnson — credentials the company leverages in active enterprise partnering efforts at BioEurope, BioEquity Europe, Swiss Biotech Day, and the GPCR-Targeted Drug Discovery Summit. The firm is led by CEO Praveen Tyle, PhD, who succeeded founding CEO Mark Groper in 2024.

Name

Orion Biotechnology

Legal name

Orion Biotechnology Canada, Ltd.

Website

https://orionbiotechnology.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Orion Biotechnology is a clinical-stage, privately held biotech that uses its proprietary PROcisionX™ discovery platform to identify and optimize peptide and small protein therapeutics against GPCRs, primarily for obesity, metabolic disorders, and immuno-oncology, with a licensing and R&D collaboration go-to-market.

Ownership category

akta.pro rank

Product category

Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• GPCR drug discovery
• Peptide therapeutics
• Obesity drug development
• Metabolic disorder treatments
• Drug discovery platform

Headquarters

HQ city

Ottawa

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Drug Development and Licensing: Pre-revenue biotech company developing proprietary GPCR-targeted therapeutics. Revenue strategy likely to include out-licensing of drug candidates, R&D collaborations, and potential strategic partnerships for co-development. The company has expressed openness to discussing out-licensing opportunities as well as R&D collaborations centered around their PROcisionX™ platform.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Orion Biotechnology is a clinical-stage biotechnology company developing precision-engineered peptide and small protein therapeutics targeting G Protein-Coupled Receptors (GPCRs), with a primary focus on obesity and metabolic disorders. The company operates the proprietary PROcisionX™ discovery platform to generate optimized therapeutic leads in less than six months and out-licenses its pipeline candidates (GPR75, GIPR, Amylin, CXCR6, OB-004) to pharmaceutical partners.

Product overview

Orion Biotechnology is a drug discovery and development company operating a single unified platform (PROcisionX™) to advance a diversified pipeline of GPCR-targeted therapeutic candidates. The platform is used to discover and optimize precision-engineered peptide and small protein analogs against metabolic GPCR targets. The current pipeline includes two GPR75 candidates for obesity, a GIPR program for metabolic disorders, an Amylin program, plus an OB-004 CCR2 antagonist and a CXCR6 first-in-class molecule for cancer immunotherapy. The company leverages phage display screening directly on cells, multiplex chemical synthesis, structure-activity matrices, and in silico/lab-based optimization to generate leads in under 6 months.

Differentiator

Problem solved

Functional benefit

Products and services

• PROcisionX™ Discovery Platform Proprietary GPCR drug discovery platform leveraging streamlined phage display, multiplex chemical synthesis, structure-activity matrices, and in silico/lab-based optimization to deliver optimized therapeutic leads in under six months. Designed to be licensed or accessed via R&D collaborations with pharmaceutical and biotechnology partners.
• GPR75 Program (Obesity Candidate) Two therapeutic candidates targeting GPR75, a novel obesity receptor, with consistent efficacy in preclinical evaluations, advancing toward clinical development for the treatment of obesity.
• GIPR Program (Metabolic/Obesity Candidate) Therapeutic candidates targeting GIPR (Glucose-dependent Insulinotropic Polypeptide Receptor) for metabolic disorders and obesity, with potent leads generated in under four months using the PROcisionX™ platform.
• Amylin Program (Metabolic Disorders Candidate) Therapeutic candidates targeting amylin for the treatment of metabolic disorders, currently at the Discovery stage of development.
• CXCR6 Discovery Program First-in-class molecule targeting CXCR6, an undrugged small protein GPCR with potential for immunotherapy treatment of solid tumor cancers, discovered in four months using the PROcisionX™ platform.
• OB-004 (CCR2 Antagonist) Best-in-class CCR2 antagonist developed by Orion Biotechnology, with demonstrated superior potency and activity in preclinical models.

Quantifiable outcome

• Discovery campaigns completed from target identification to optimized lead in less than 6 months - a fraction of industry standard time
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Structure Therapeutics: Clinical-stage biotech developing oral small molecule GPCR-targeted therapeutics for metabolic diseases including obesity. Most direct comparable: also targets metabolic GPCRs with a proprietary discovery platform, has advanced candidates into clinical trials, and pursues pharma partnerships.
• Septerna: GPCR-focused biotech with a native GPCR platform for drug discovery across multiple disease areas. Highly comparable technology approach and target class to Orion's PROcisionX™ platform.
• Crinetics Pharmaceuticals: Clinical-stage biotech developing peptide and small molecule therapeutics targeting GPCRs, primarily in endocrine and metabolic diseases. Most advanced GPCR-focused peer with approved product (palopegteriparatide) and a pipeline directly comparable in mechanism class.
• Rhythm Pharmaceuticals: Commercial-stage biotech focused on rare endocrine and metabolic diseases via melanocortin-4 receptor (MC4R) — a GPCR — pathway. Comparable in targeting metabolic GPCRs with peptide/small molecule approaches.
• Keros Therapeutics: Clinical-stage biotech developing engineered proteins and peptides targeting TGF-β superfamily and related pathways. Comparable as a protein/peptide engineering biotech with similar pipeline stage and therapeutic focus.
• Zealand Pharma: Clinical and commercial-stage peptide therapeutics company with metabolic disease focus, including obesity (amylin analogs) and GPCR-targeted peptides. Directly overlaps Orion's peptide-based metabolic disease pipeline.
• Gubra: Danish biotech with peptide-based obesity/metabolic pipeline (including amylin and GIP analogs) and a proprietary discovery platform. Closely matches Orion's peptide engineering approach and metabolic focus.
• Hanmi Pharmaceutical: Korean pharma with pipeline of peptide-based obesity/metabolic candidates (including GLP-1, GIP, amylin class molecules) and history of major out-licensing deals. Comparable as a peptide-focused metabolic disease developer pursuing global pharma partnerships.

Broad incumbents

• Novo Nordisk: Global leader in obesity/metabolic therapeutics (Wegovy, Ozempic) and dominant incumbent in GPCR-targeted peptide drugs. Sets the standard of care Orion's metabolic GPCR candidates must beat or differentiate against.
• Eli Lilly: Global pharma leader in obesity (Zepbound/Mounjaro) with active GPCR and peptide R&D via Lilly Catalyze. Potential Orion partner or acquirer and the dominant commercial benchmark in target indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/orion_biotech
• LinkedInlinkedin.com/company/orion-biotechnology

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orion Biotechnology